


Techcyte and Cytobay Partner to Create Non-Invasive Digital Diagnostic Test for Bladder Cancer

OREM, UT, UNITED STATES, May 26, 2022 /EINPresswire.com/ -- Bladder cancer is one of the most common cancers and has a high recurrence rate. After successful treatment, it is recommended that survivors be tested every three to six months for the first two years, every six to twelve months for years three to four, and then yearly from then on. This invasive test for recurrent cancer is painful, time-consuming, and expensive. Despite its high risk of recurrence, less than half of patients actually follow these guidelines. In an effort to improve these numbers, Techcyte and Cytobay are proud to announce their collaboration in the creation of a non-invasive test that will redefine bladder cancer surveillance.



Cytobay was founded by Dr. Wenjiang Chu with the vision to develop a non-invasive methodology to diagnose cancer and monitor disease progression. Dr. Chu states "Our novel technology enables the evaluation of single cell cytomorphologic and molecular profiles simultaneously, especially in clinical samples only containing a minimal amount of target cells. We have automated the slide preparation staining process to highlight uroepithelial carcinoma cells and subsequently transform the landscape of bladder cancer diagnosis."

Cytobay approached Techcyte to utilize its Clinical Pathology AI platform to analyze the cells and complete the diagnostic process. "We are on the cutting edge of new non-invasive cancer diagnostics," says Cytobay's President and COO, Mitchell Aicher, "Our collaboration with Techcyte will allow us to provide revolutionary, accurate and cost effective cancer diagnostics to those who need it most."

The deep machine learning AI created by Techcyte will accurately and efficiently identify cancerous bladder cells in a fraction of the time and cost compared to current methods. Techcyte's technology is being used in laboratories for cervical cytology, bacteriology,

hematology, and parasitology. This collaboration opens the door for Techcyte to become the first AI platform for bladder cancer diagnostics.

Studies show that 75% of bladder cancer is treatable if detected early. "There is a big need for non-invasive, accurate, and quick diagnostic testing for bladder cancer." said Techcyte CEO Ben Cahoon. " This collaboration allows us to make a big impact in cancer survivors' lives using AI-driven diagnostics."

AI validation studies are underway, with the product projected to be available winter of 2022.

###

About Techcyte

Headquartered in Orem, Utah, Techcyte, Inc. was founded in 2013 and is the world leader in AI-based cellular digital diagnostics. Techcyte's AI-powered Clinical Pathology Platform uses deep machine learning to perform automated analysis of whole slide microscopy images, revolutionizing digital diagnostics for human, animal and environmental clinics and labs.

Visit techcyte.com for more information.

Techcyte's clinical pathology platform is CE marked in the European Union and is for Research Use Only in the United States.

About Cytobay

Founded in Los Angeles in 2020, Cytobay Laboratories, Inc. is on the leading edge of Next Generation Cancer Diagnostics. Cytobay Laboratories proprietary staining technology revolutionizes cancer testing to make it more reliable, cost-effective, and convenient.

Visit cytobaylabs.com for more information.

Troy Bankhead

Techcyte

+1 435-210-6200

troy.bankhead@techcyte.com

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/573793692>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.